Nuo Therapeutics (AURX) EBITDA Margin (2010 - 2026)
Nuo Therapeutics (AURX) posted EBITDA Margin of -7.93% for Q2 2026, up 81.89 percentage points from -89.83% a year earlier.
Powered by 
Analysis
Nuo Therapeutics (AURX) EBITDA Margin (2010 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, EBITDA Margin at Nuo Therapeutics was -40.05%, up 90.68 percentage points year-over-year; for FY2025, it came in at -73.37%, up 104.98 percentage points from FY2024.
- Annual EBITDA Margin has increased for three consecutive years, with a three-year change of +2878.76 percentage points (FY2022 to FY2025).
- In prior years, Nuo Therapeutics' EBITDA Margin was -178.35% in FY2024 (+339.78 pp), -518.13% in FY2023 (+2434.00 pp) and -2952.13% in FY2022.
- The Q2 2026 figure stands as the highest quarterly EBITDA Margin since Q4 2019.
- The year-over-year gain in EBITDA Margin has ranged between 57.72 percentage points (Q2 2025) and 2038.50 percentage points (Q3 2023) over the last five years.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 254.21 Bn | 233.23 Bn | 4.88 Bn | 24.20% |
| 2 | Abbott Laboratories | 176.12 Bn | 146.55 Bn | 7.27 Bn | 21.86% |
| 3 | Danaher | 164.23 Bn | 148.04 Bn | 3.61 Bn | 28.51% |
| 4 | Intuitive Surgical | 155.68 Bn | 135.10 Bn | 1.96 Bn | 41.08% |
| 5 | Medtronic | 121.85 Bn | 87.10 Bn | 6.34 Bn | 25.55% |
| 6 | Stryker | 117.33 Bn | 103.45 Bn | 4.50 Bn | 29.67% |
| 7 | Boston Scientific | 66.63 Bn | 61.40 Bn | 3.85 Bn | 28.17% |
| 8 | Becton Dickinson | 54.34 Bn | 51.49 Bn | 2.32 Bn | 24.62% |
| 9 | Edwards Lifesciences | 51.61 Bn | 35.62 Bn | 1.35 Bn | 31.93% |
| 10 | Nuo Therapeutics | 61.03 Mn | 59.20 Mn | 1.17 Mn | -7.93% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.93% |
| Dec 31, 2025 | -50.64% |
| Sep 30, 2025 | -50.09% |
| Jun 30, 2025 | -89.83% |
| Mar 31, 2025 | -150.67% |
| Dec 31, 2024 | -156.43% |
| Sep 30, 2024 | -154.58% |
| Jun 30, 2024 | -147.55% |
| Mar 31, 2024 | -300.75% |
| Dec 31, 2023 | -329.08% |
| Sep 30, 2023 | -338.39% |
| Jun 30, 2023 | -734.23% |
| Mar 31, 2023 | -1,392.95% |
| Dec 31, 2022 | -1,297.86% |
| Sep 30, 2022 | -2,376.89% |
| Dec 31, 2019 | 3,061.20% |
| Sep 30, 2019 | -25.59% |
| Jun 30, 2019 | -786.00% |
| Mar 31, 2019 | -1,439.42% |
| Dec 31, 2018 | 23.60% |
API Access
Nuo Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=AURX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "AURX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=AURX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();